Milestone Pharmaceuticals Enrolls First Canadian Patient In Phase 3 Trial Of Etripamil For AFib With Rapid Heart Rate
Share
Why It Matters
Milestone Pharmaceuticals started testing a new heart medicine in Canada. Watch for trial progress updates to see if the drug works well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.